Novel Mutations in IL-10 Promoter Region -377 (C>T), -150 (C>A) and their Association with Psoriasis in the Saudi Population

  • Al-Balbeesi, Amal O. (Department of Dermatology, King Khalid University Hospital, King Saud University) ;
  • Halwani, Mona (Department of Dermatology, King Khalid University Hospital, King Saud University) ;
  • Alanazi, Mohammad (Genome Research Chair, Department of Biochemistry, College of Science, King Saud University) ;
  • Elrobh, Mohammad (Genome Research Chair, Department of Biochemistry, College of Science, King Saud University) ;
  • Shaik, Jilani P. (Genome Research Chair, Department of Biochemistry, College of Science, King Saud University) ;
  • Khan, Akbar Ali (Genome Research Chair, Department of Biochemistry, College of Science, King Saud University) ;
  • Parine, Narasimha Reddy (Genome Research Chair, Department of Biochemistry, College of Science, King Saud University)
  • Published : 2015.03.04


Background: Psoriasis, a common cutaneous disorder characterized by inflammation and abnormal epidermal proliferation with a prevalence of 2-3% in the general population, may be linked to certain types of cancer. Several studies have reported an association between interleukin 10 (IL-10) variant polymorphisms and inflammatory diseases such as psoriasis vulgaris although the results vary according to the population studied. No studies have been performed in the Saudi population. The present study concerned novel variants and other genetic polymorphisms of the promoter and exonic regions of the IL10 gene in patients with moderate to severe psoriasis and potential differences in genotype compared to a group of healthy volunteers. Materials and Methods: Patients with moderate to severe psoriasis and healthy controls with no personal or family history of psoriasis were selected from the central region of Saudi Arabia. Polymorphisms of the IL 10 gene of both groups were genotyped. Results: We observed two novel variants in 5'UTR region of the promoter precursor with higher prevalence of the genotype with both wild-type alleles in patients compared to the healthy control group. The differences at positions -377 and -150 were significantly associated with disease, both the variants conferred strong protection against psoriasis in Saudi patients. Conclusions: This observation provides further support for the importance of the part that IL10 plays in the pathophysiology of this disease. Confirmation of our findings in larger populations of different ethnicities would provide evidence for the role of IL-10 in psoriasis.


Supported by : King Saud University


  1. Acuner-Ozbabacan SE, Engin HB, Guven-Maiorov E, et al (2014). The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics, 15, 2.
  2. Alamartine E, Berthoux P, Mariat C, et al (2003) Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol, 120, 99-103.
  3. Alanazi M, Pathan AAK, Shaik JP, et al (2013). The C Allele of a synonymous SNP (rs1805414, Ala284Ala) in PARP1 is a risk factor for susceptibility to breast cancer in Saudi patients. Asian Pac J Cancer Prev, 14, 3051-6.
  4. Bethea D, Fullmer B, Syed S, et al (1999) Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci, 19, 78-88.
  5. Burden AD, Javed S, Bailey M (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol, 110, 958-60.
  6. Haanpaa MT, Nurmikko, Hurme M (2002) Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis, 34, 112-4.
  7. Howell WM, Turner SJ, Bateman AC, et al (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun, 2, 25-31.
  8. Jacob SE, Nassiri M, Kerdel FA et al (2003). Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediator Inflammat, 12, 309-13.
  9. Karam RA, Zidan HE, Khater MH (2014) Polymorphisms in the TNF-$\alpha$ and IL-10 gene promoters and risk of psoriasis and correlation with disease severity. Cytokine, 66, 101-5.
  10. Kim SC, Glynn RJ, Giovannucci E, et al (2014). Risk of highgrade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis, [Epub ahead of print]
  11. Langan SM, Seminara NM, Shin DB, et al (2012). Prevalence of metabolic syndrome in patients with psoriasis: a populationbased study in the United Kingdom. J Invest Dermatol, 132, 556-62.
  12. Liu Y, Helms C, Liao W, et al (2008). A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS genetics, 4, 1000041.
  13. Mangangcha, Irengbam R, Pankaj J, et al (2011) Differential serum cytokine levels are associated with cytokine gene polymorphisms in north Indians with active pulmonary tuberculosis. Infect Genet Evol, 11, 1015-22.
  14. Moore KW, de Waal Malefyt R, Coffman RL et al (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19, 683-765.
  15. Neurath MF (2014). Cytokines in inflammatory bowel disease. Nat Rev Immunol, 14, 329-342.
  16. Pouplard C, Brenaut E, Horreau C, et al (2013). Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol, 27 Suppl 3, 36-46.
  17. Sabat R, Grütz G, Warszawska K, et al (2010) Biology of interleukin-10. Cytokine Growth Factor Rev, 21, 331-44.
  18. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A Laboratory Manual (second ed.) Cold Spring Harbor Laboratory Press, New York
  19. Tagore A, Gonsalkorale WM, Pravica V, et al (1999) Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens, 54, 386-90.
  20. Wang L, Li K, Xu Q, et al (2013). Potential synergy between SNP and CpG-A or IL-$1{\beta}$ in regulating transcriptional activity of IL-20 promoter. J Invest Dermatol, 134, 389-95.

Cited by

  1. ) vol.24, pp.15, 2015,
  2. Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups pp.1179-1888, 2017,
  3. Advances in Understanding the Immunological Pathways in Psoriasis vol.20, pp.3, 2019,